These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 19134031)

  • 1. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of haemophilic arthropathy in haemophilic children with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Nov; 14 Suppl 6():1-3. PubMed ID: 19134025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
    Rodriguez-Merchan EC; Hedner U; Heijnen L; Jimenez-Yuste V; Lee CA; Morfini M; Querol F; Roosendaal G; Santagostino E; Solimeno LP
    Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When should prophylaxis therapy in inhibitor patients be considered?
    Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
    Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
    Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
    Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.